Effect of temozolomide on male gametes: an epigenetic risk to the offspring?

Introduction Temozolomide is an oral alkylating agent with proven efficacy in recurrent high-grade glioma. The antitumour activity of this molecule is attributed to the inhibition of replication through DNA methylation. However, this methylation may also perturb other DNA-dependent processes, such a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of assisted reproduction and genetics Vol. 30; no. 6; pp. 827 - 833
Main Authors: Berthaut, I., Montjean, D., Dessolle, L., Morcel, K., Deluen, F., Poirot, C., Bashamboo, A., Mcelreavey, K., Ravel, C.
Format: Journal Article
Language:English
Published: Boston Springer US 01-06-2013
Springer Nature B.V
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Temozolomide is an oral alkylating agent with proven efficacy in recurrent high-grade glioma. The antitumour activity of this molecule is attributed to the inhibition of replication through DNA methylation. However, this methylation may also perturb other DNA-dependent processes, such as spermatogenesis. The ability to father a child may be affected by having this treatment. Here we report a pregnancy and a baby born after 6 cures of temozolomide. Methods The quality of gametes of the father has been studied through these cures and after the cessation of treatment. Sperm parameters, chromosomal content and epigenetic profiles of H19 , MEST and MGMT have been analysed. Results Sperm counts decrease significantly and hypomethylation of the H19 locus increase with time even staying in the normal range. Conclusion This is the first report of an epigenetic modification in sperm after temozolomide treatment suggesting a potential risk for the offspring. A sperm cryopreservation before the initiation of temozolomide treatment should be recommended.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1058-0468
1573-7330
DOI:10.1007/s10815-013-9999-8